Physician profile
William J Morris
NPI 1720147150
$1,364.29
in general payments reported to CMS, 2019-2025
11 companies · $1,217 in 2025
The $1,217 reported for 2025 was more than what 96% of Hospice and Palliative Medicine (Internal Medicine) providers received nationally (typical 2025 total: $77.77).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $148 · 2025: $1,217.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Long Term Medical Supply Or Device Loan: $997 · Food and Beverage: $367.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Long Term Medical Supply Or Device Loan | $997.00 |
| Food and Beverage | $367.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,049.97 | 2025 | |
| Janssen Biotech, INC. | $73.99 | 2024-2025 | Talvey, Tecvayli, Darzalex |
| Daiichi Sankyo INC. | $51.37 | 2024-2025 | Enhertu |
| Eisai INC. | $31.84 | 2024 | |
| Pharmaessentia USA Corporation | $31.11 | 2025 | Besremi |
| Astellas Pharma US INC | $28.31 | 2024 | Padcev |
| Merck Sharp & Dohme LLC | $24.06 | 2024 | Keytruda |
| Genmab U.S., INC. | $22.32 | 2025 | Epkinly |
| Coherus Oncology, INC. | $18.46 | 2024 | |
| Incyte Corporation | $16.67 | 2025 | Monjuvi |
| Astrazeneca Pharmaceuticals LP | $16.19 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Morris listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.